Concluding Reflections and Remarks
M. tuberculosis is mainly transmitted by the airborne route and remains the chief mycobacterial pathogen; M. bovis seems to have played a very minor role in wartime-associated TB resurgences. M. tuberculosis is most likely transmitted where population density is high and thus opportunity for exposure is increased. Transmission is much more likely to occur indoors than outdoors where tubercle bacilli are rapidly dispersed in the ambient air. Thus, where the climate is cold, people collect indoors, and poverty forces crowded living conditions that facilitate transmission. The latter situations are typically enhanced during wartime, and the tuberculin skin test surveys among children in Lebanon during the civil war discussed above may thus make a case in point. Airborne transmission of M. tuberculosis takes center stage in the pathogenetic sequence of TB (Fig. 1). Because increased transmission has long-term implications due to the open-ended incubation period of TB, it provides a key to better understand the epidemiology of TB in general and during wartime specifically. However, there are serious methodological barriers to ascertain transmission and there is scarcity of information about it.
We have alluded to factors that may increase the risk of progression from latent infection with M. tuberculosis to TB, yet have refrained from a comprehensive discussion that has been the focus of more general discussions of the epidemiologic basis of TB control [3, 79, 80]. Risk factors for progression from latent infection with M. tuberculosis to TB as they pertain in particular to periods of war will be addressed in chapter 3. We have at length tried to determine whether case fatality or faster speed at which untreated TB progresses to death is changed during war times, but have not been able to determine this in a satisfactory manner.
Finally, at the outset we have put the importance of data accuracy above all. It is always difficult to be sure about the numerator and the denominator, and this is particularly compounded during civil strife, armed conflict, and war. Data reported during such times will thus always have to be viewed with great reservation.
References
1Diagnostic standards and classification of tuberculosis in adults and children. This official statement of the American Thoracic Society and the Centers for Disease Control and Prevention was adopted by the ATS Board of Directors, July 1999. This statement was endorsed by the Council of the Infectious Disease Society of America, September 1999. Am J Respir Crit Care Med 2000;161:1376–1395.
2Rieder HL: Opportunity for exposure and risk of infection: the fuel for the tuberculosis pandemic. Infection 1995;23:1–3.
3Rieder HL: Epidemiologic basis of tuberculosis control, ed 1. Paris, International Union against Tuberculosis and Lung Disease, 1999.
4Rieder HL, Cauthen GM, Comstock GW, Snider DE Jr: Epidemiology of tuberculosis in the United States. Epidemiol Rev 1989;11:79–98.
5Ferebee SH, Mount FW: Tuberculosis morbidity in a controlled trial of the prophylactic use of isoniazid among household contacts. Am Rev Respir Dis 1962;85:490–521.
6Ferebee SH: Controlled chemoprophylaxis trials in tuberculosis. A general review. Adv Tuberc Res 1970;17:28–106.
7Pollock JM, Andersen P: The potential of the ESAT-6 antigen secreted by virulent mycobacteria for specific diagnosis of tuberculosis. J Infect Dis 1997;175:1251–1254.
8von Pirquet C: Der diagnostische Wert der kutanen Tuberkulinreaktion bei der Tuberkulose des Kindesalters auf Grund von 100 Sektionen. Wien Klin Wochenschr 1907;(No. 88):1123–1128.
9Mendel F: Die von Pirquetsche Hautreaktion und die intravenöse Tuberkulinbehandlung. Med Klin 1908;(No. 12):402–404.
10Mantoux C: L’intradermo-réaction à la tuberculine et son interprétation clinique. Presse Méd 1910;(No. 2):10–13.
11Margolis ML, Van Uitert BL: Anergy in tuberculosis. Biomed Pharmacother 1985;39:292–298.
12Chaparas SD, Vandiviere HM, Melvin I, et al: Tuberculin test. Variability with the Mantoux procedure. Am Rev Respir Dis 1985;132:175–177.
13Snider DE Jr: The tuberculin skin test. Am Rev Respir Dis 1982;125:108–118.
14Auersbach K: Zur Einführung der Calmette-Impfung in Deutschland. Ärztl Wschr 1946;1:314–317.
15van Geuns HA: BCG vaccination in school-leavers? Selected Papers 1987;23:25–50.
16Anonymous: BCG vaccination. A memorandum from the Ministry of Health. Tubercle 1949;30:183.
17Snider DE Jr, Cauthen GM: Tuberculin skin testing of hospital employees: infection, “boosting,” and two-step testing. Am J Infect Control 1984;12:305–311.